P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

British Journal of Cancer

Volumn 83, Issue 6, 2000, Pages 817-825

  Sandor, V ^a   Senderowicz, A ^b   Mertins, S ^a   Sackett, D ^a   Sausville, E ^b   Blagosklonny, M V ^a   Bates, S E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Cyclin; Cytotoxicity; Experimental therapeutic; P21

Indexed keywords

CELL EXTRACT; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR; FR 901228; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL CLONE; CELL CYCLE; CELL CYCLE G1 PHASE; CLINICAL TRIAL; CYTOTOXICITY; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 0033822112     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1327     Document Type: Article

References (46)

1. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27K1PI
2. p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells
3. A node between proliferation, apoptosis, and growth arrest
4. Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells
5. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter
6. Retinoblastoma protein recruits histone deacetylase to repress transcription
7. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
8. Restriction point control of cell growth by a labile protein: Evidence for increased stability in transformed cells
9. Sodium butyrate inhibits histone deacetylation in cultured cells
10. P53, through p21 (WAF1/CIP1), induces cyclin DI synthesis
11. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity
12. WAF1, a potential mediator of p53 tumor suppression
13. Use of the cyclin E restriction point to map cell arrest in G(I)-induced by N-butyrate, cycloheximide, staurosporine, lovastatin, mimosine and quercetin
14. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia
15. Oncoprotein networks
16. Expression of transcription factor E2F1 induces quiescent cells to enter S-phase
17. Phosphorylation of retinoblastoma protein assayed in individual HL-60 cells during their proliferation and differentiation
18. Oxamflatin is a novel antitumor compound that inhibits mammalian historic deacetylase
19. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to anti-leukemia therapy
20. Rhodamine efflux patterns predict P-gtycoprotein substrates in the National Cancer Institute drug screen
21. Role of the histone deacetylase complex in acute promyelocytic leukemia
22. Rb interacts with histone deacetylase to repress transcription
23. Retinoblastoma protein repress transcription by recruiting a histone deacetylase
24. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
25. Toward an understanding of the functional complexity of the E2F and retinoblastoma families
26. E2F-dependent regulation of human MYC: Trans-activation by cyclins D1 and A overrides tumour suppressor protein function
27. A restriction point for control of normal animal cell proliferation
28. Genetic determinants of p53-induced apoptosis and growth arrest
29. Effects of a novel antitumor depsipeptide. FR901228, on human breast cancer cells
30. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
31. Cancer cell cycles
32. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10
33. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the SP1 sites
34. p21WAF1/Cip1 inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption
35. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. Antitumor activities on experimental tumors in mice
36. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity
37. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells
38. Butyrate-induced Gl arrest results from p21-independent disruption of retinoblastoma protein-mediated signals
39. p2l Is necessary for the p53-mediated G1 arrest in human cancer cells
40. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
41. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression
42. The retinoblastoma protein and cell cycle control
43. Normal p53 status and function despite the development of drag resistance in human breast cancer cells
44. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition
45. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF
46. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1 and cyclin-dependent kinases